Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...
A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
News Medical on MSN4d
Opioid δ-receptor agonists show promise for treating IBS-like symptomsResearch reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...
GlobalData on MSN7h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback